ReviewFrontiers in bioengineering and biotechnology2025
3D bioprinting for bile duct tissue engineering: current status and prospects.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Organoids in Pediatric Congenital Hepatobiliary Diseases: Current Status and Progress in Clinical Translational Research.Biomedicines · 2026Review
- Fabricating transplantable, vascularized, and cholangiogenic bioartificial livers via three-dimensional bioprinting: a promising therapeutic strategy for liver failure.Hepatobiliary surgery and nutrition · 2026Article
- From repair to risk: ICC-like fibrosis following 3D bioprinted bile duct reconstruction - a letter to the editor.Annals of medicine and surgery (2012) · 2026Article
- Applications of 3D models in cholangiocarcinoma.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile duct disorders, including cholangiocarcinoma, primary sclerosing cholangitis, and iatrogenic injuries, pose significant clinical challenges due to limited regenerative capacity and the complexity of the biliary tree. In recent years, 3D bioprinting has emerged as a promising approach for bile duct tissue engineering by providing patient-specific geometries and facilitating the spatial organization of cells, scaffolding materials, and bioactive factors. This review presents a comprehensive overview of 3D bioprinting techniques for bile duct tissue engineering, focusing on fundamental principles, biomaterial selection, current achievements, key challenges, and future perspectives. We systematically discuss the latest technological breakthroughs, highlight emerging innovations such as organoid-based strategies and microfluidic-assisted 3D printing, and evaluate the prospects for clinical translation. Finally, we outline the main challenges-such as biocompatibility of materials, vascularization, immunological barriers, standardization of protocols, and regulatory hurdles-and propose directions for future research, emphasizing multidisciplinary collaboration and translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.